Abstract
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Despite increasing knowledge of ovarian cancer biology and advances in treatment efficacy, the survival rate of patients with EOC has not improved over the past two decades. Patients with an advanced disease often relapse due to the development of chemoresistance. Recent in vivo and in vitro studies have shown insight into the mechanisms of such drug resistance, including a potential role for microRNAs (miRNA, miR) in the process of chemoresistance. In this review, we provide an overview of current therapeutic targets of miRNA-associated chemoresistance in EOC and discuss potential therapeutic values and molecular mechanisms by which miRNAs influence the development and reversal of chemoresistance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
